TheraRadar
← Back
Data updated: Jun 28, 2026

PHOTOCURE ASA

Pharma
OncologyDermatology Execution: Good

PHOTOCURE ASA is a pharmaceutical company focused on Oncology, Dermatology.

2010
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

PHOTOCURE ASA at a Glance

  • Fast trial execution (8 months median completion)

PHOTOCURE ASA's Key Drugs

PHOTOCURE ASA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PHOTOCURE ASA's Recent FDA Approvals

New NDA/BLA approvals for PHOTOCURE ASA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PHOTOCURE ASA's Therapeutic Areas

PHOTOCURE ASA's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Dermatology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 68%
1 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Dermatology 32%
0 drugs Phase 2: 4

PHOTOCURE ASA's Top Competitors

PHOTOCURE ASA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Oncology, Dermatology
Baxter specialty
Oncology, Dermatology
Eli Lilly big-pharma
Oncology, Dermatology
Bayer big-pharma
Oncology, Dermatology
KING PHARMS big-pharma
Oncology, Dermatology

PHOTOCURE ASA Pipeline Snapshot

PHOTOCURE ASA has 8 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 5 Phase 2 and 1 Phase 1.

2
Phase 3
5
Phase 2
1
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Oncology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/2 completed
  • • Speed: 8 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges